Human Lungs Harbor 87,000 Long-Lived T Cells Against Multiple Pathogens, Challenging Mouse Models
Updated
Updated · BIOENGINEER.ORG · Jul 28
Human Lungs Harbor 87,000 Long-Lived T Cells Against Multiple Pathogens, Challenging Mouse Models
3 articles · Updated · BIOENGINEER.ORG · Jul 28
Summary
A Nature Immunology study mapped a long-lived reservoir of tissue-resident memory T cells in human lungs, showing they are positioned to respond rapidly to infection rather than being detected mainly in blood.
More than 87,000 T_RM cells from 40 people aged 61 to 83 revealed lung-resident immunity against influenza A, SARS-CoV-2, RSV, parainfluenza and metapneumovirus, alongside CMV and EBV.
The lung archive also included T_RM cells reactive to Bordetella pertussis and Aspergillus fumigatus, indicating the tissue preserves adaptive memory against viral, bacterial and fungal threats.
Mouse comparisons highlighted a key translational gap: similar lung T_RM populations fade quickly in mice, while human cells can persist for months to years.
That persistence could reshape vaccine design, because blood-based immune readouts may miss the most relevant protection if effective respiratory vaccines must build T_RM cells directly in lung tissue.
If our lungs store long-lasting immune defenders, why do we still suffer from repeated respiratory infections year after year?
Could the physical stiffness of our lung tissue be the secret switch that grants immune cells their extraordinary lifespan?
If human lungs harbor immune cells for years, what other medical dogmas based on mice are completely wrong?
The Human Lung’s 87,000-Cell TRM Army: Redefining Local Immunity, Vaccine Design, and Inflammatory Risk
Overview
This report reveals how the human lung, constantly exposed to environmental and microbial antigens, builds a powerful and long-lasting defense with tissue-resident memory T cells (TRMs). Unlike mice, whose TRM cells quickly disappear due to clean lab conditions, humans develop stable TRMs that anchor in lung tissue and cannot escape into the blood. These cells respond rapidly to pathogens by releasing cytokines, which not only protect against infections—even in people who lack antibodies—but also recruit other immune cells and help distribute antibodies locally. However, when TRMs become overactive, especially in polluted or allergen-rich environments, they can drive chronic lung diseases like asthma and fibrosis, highlighting the need for therapies and vaccines that balance protection with the risk of inflammation.